More and more American firms are calling for the Trump administration to resolve its conflict with China.World Economyread more
The Fed is not likely to make a move on interest rates when it meets this week, but it should clear the way for a rate cut later in the summer.Market Insiderread more
Target CEO Brian Cornell apologized to customers for a disappointing weekend after the company experienced outages that shut down its cash registers and credit-card processors...Retailread more
American Airlines is ordering Airbus' new A321XLR, according to a source familiar with details of the agreement.Paris Air Showread more
Huawei CEO Ren Zhengfei tells CNBC the company's business is still strong in China.Technologyread more
Here are the biggest calls on Wall Street on WednesdayInvestingread more
The pilots union for Southwest Airlines says it will ask Boeing for compensation to cover legal costs and lost income for pilots due to the 737 Max grounding.Airlinesread more
Amazon announced an all-new Kindle Oasis on Wednesday morning with a feature that lets you adjust the screen to warmer tones for easier reading at night.Technologyread more
But BlackRock's global fixed income chief also says he doesn't think the Fed will announce a rate cut until July.Market Insiderread more
Panera Bread has been testing a menu specifically for dinner and plans to expand the pilot to a new market next month.Restaurantsread more
Beyond Meat's plant-based protein story holds appeal to the youngest generation of investors. But its shares, BYND, have done so well in such a short time that it may lead...Invest in You: Ready. Set. Grow.read more
Ligand gets royalties on sales of Amgen's Kyprolis drug, which treats a form of incurable blood cancer. The drug generated $172 million in revenue in the second quarter, according to Reuters, and was expected to generate peak annual sales of about $2.3 billion.
Amgen Executive Vice President of Research and Development Sean Harper said the study was designed to explore Kyprolis dosing regimens, noting that the the trial did not meet its goal in improving progression-free survival versus Velcade in patients who had not yet been treated for the disease.
"We remain committed to exploring Kyprolis in combination with other agents to advance the treatment of multiple myeloma," Harper said.
Kyprolis has already been approved by the U.S. Food and Drug Administration for patients with relapsed or refractory multiple myeloma, who have previously been treated.
Dr. Andrzej Jakubowiak from the University of Chicago Medical Center said during a conference call that although the results were disappointing, they were predictable to some extent.
"This was the wrong combination chosen for this evaluation, wrong duration of treatment as well, which we now know and is potentially important," he said.
Kyprolis is also being tested in a separate late-stage trial in combination with Celgene's Revlimid and the steroid dexamethasone, or KRd.
Shares of Ligand have fallen 8 percent for the year, closing at $99.64 a share. Amgen was down about 1 percent for the day, but up more than 5 percent for the year, closing at $171.63 a share.
--Reuters contributed to this report.